Dr. Reddy to lead local sales and marketing of K-CAB under the brand name ‘PCAB’
[by Ji, Yong Jun] HK inno.N announced on September 17 that it has officially launched K-CAB (tegoprazan), its novel gastroesophageal reflux disease (GERD) drug, in the Indian market. Local sales and marketing will be managed by the global pharmaceutical company Dr. Reddy's Laboratories Ltd.
K-CAB received regulatory approval in 스피드 바카라 사이트 this past May under the brand name PCAB 50mg for the treatment of erosive and non-erosive GERD, as well as gastric ulcers. In 2022, HK inno.N entered into an agreement with Dr. Reddy's Laboratories to export finished K-CAB tablets to 스피드 바카라 사이트 and six other emerging markets.
As of last year, the 스피드 바카라 사이트n market for peptic ulcer treatment was valued at about KRW 1.52 trillion (approximately USD 1.1 billion), ranking fourth globally after China, the United States, and Japan. With 스피드 바카라 사이트 recognized as the world's most populous nation and an estimated 38% of its population affected by gastroesophageal reflux disease (GERD), the company emphasized that effective management of the condition is becoming increasingly critical.
Dr. Reddy's announced plans to reshape the local GERD market by introducing K-CAB (스피드 바카라 사이트n brand name: PCAP) 50mg in the 스피드 바카라 사이트n market later this month. "The launch of PCAB represents the culmination of our efforts to deliver innovative treatment options in the GERD field. We have established a strong and trusted presence in this area through our diverse portfolio, including Omez (omeprazole), Razo (rabeprazole), and Vono (vonoprazan),” stated M.V. Ramana, Executive Vice President and Head of Branded Markets (스피드 바카라 사이트 and Emerging Countries) at Dr. Reddy's Laboratories.
"By strengthening the synergy of our partnership with HK inno.N, we aim to address the gap in GERD management and deliver innovative therapies that enhance patient access," Ramana further commented.
“We are pleased that K-CAB has entered 스피드 바카라 사이트, one of the world’s largest pharmaceutical markets. In line with the 스피드 바카라 사이트n product name ‘PCAB,’ we aspire for K-CAB to establish itself as a globally recognized innovative novel drug representing the P-CAB series and to offer new treatment options for 스피드 바카라 사이트n patients,” said Kwak Dal-won, CEO of HK inno.N.